Blocks 26S proteasome activity by inhibiting the ubiquitin C-terminal hydrolase 5 (UCHL5) and ubiquitin-specific peptidase 14 (USP14) activities of the 19S regulatory subunit without affecting the catalytic activity of the 20S core subunit. b-AP15 displays several differences to bortezomib including insensitivity to over-expression of the anti-apoptotic mediator Bcl-2 and anti-tumor activity in four solid tumor models.

b–AP15, NSC–687852, 3,5–Bis[(4–nitrophenyl)methylene]–1?–(1–oxo–2–propene–1–yl)–4–piperidone

≥98% by HPLC.

Soluble in DMSO (35 mg/ml)

Pale yellow powder

Suitable for validation studies of the deubiquitinating activities of the 19S regulatory particle as a drug target, as well as cell-based and in vitro characterization UCH-L5 or USP14 activity.

Protect from moisture.

Ubiquitin Enzymes

Inhibitors/Activators